Nxera Pharma Achieves Development Milestone In Collaboration With Eli Lilly Targeting Metabolic Diseases
02/06/2025 24:32
June 2 (Reuters) - Nxera Pharma Co Ltd 4565.T: NXERA PHARMA CO LTD: NXERA PHARMA ACHIEVES DEVELOPMENT MILESTONE IN COLLABORATION WITH ELI LILLY TARGETING METABOLIC DISEASES NXERA PHARMA CO LTD: UNDER TERMS OF AGREEMENT, NXERA IS ELIGIBLE TO RECEIVE DEVELOPMENT AND COMMERCIAL MILESTONES TOTALLING UP TO US$694 MILLION, PLUS TIERED ROYALTIES ON GLOBAL SALES Source text: ID:nTSra8c93e Further company coverage: 4565.T (Reporting by Tokyo Newsroom) ((+81345201189;))
Recent news on Nxera Pharma
See all newsNxera Pharma Submits Marketing Authorization Application For Vamorolone In South Korea For Treatment Of Duchenne Muscular Dystrophy
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Brief: Nxera Pharma - Entered Into Exclusive License, Supply And Commercialization Agreement With Synmosa For Quviviq Across Eight Asia-Pacific Markets
Brief: Nxera Announces Successful Resolution Of Minig Patent Infringement Action
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up